

glasdegib (DAURISMO)

Diagnosis Considered for Coverage:

- Acute myeloid leukemia (AML)

Coverage Criteria:

For acute myeloid leukemia (AML):

- Dose does not exceed 100 mg per day, **and**
- Being used in combination with cytarabine, **and**
- One of the following:
 - Patient has already been treated for AML (refractory), **or**
 - Patient is newly diagnosed and either:
 - 75 years or older, **or**
 - Prescriber attestation that patient is not a candidate for intensive/standard induction chemotherapy, **or**
 - Patient has at least one of the following significant comorbidities:
 - severe cardiac disease, **or**
 - baseline serum creatinine > 1.3 mg/dL (renal impairment), **or**
 - ECOG status 2 or more: patient is ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% waking hours)

Coverage Duration: one year

Effective Date: 6/28/2023